FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385973380> ?p ?o ?g. }

• W4385973380 endingPage "101919" @default.
• W4385973380 startingPage "101919" @default.
• W4385973380 abstract "Even though leukemia murine models are valuable tools for new drug therapy studies, most of these models consist of immunocompromised mice, which do not exhibit immune responses. In order to obtain an adequate leukemia model, we established an acute promyelocytic leukemia transplantation-based model (PML/RARa) in immunocompetent BALB/c mice, thus making it possible to study drug-induced cellular immune responses in leukemia. The development of PML/RARa leukemia was confirmed by leukocytosis (76.27 ± 21.8 vs. 3.40 ± 1.06; P < 0.0001), anemia (7.46 ± 1.86 vs. 15.10 ± 0.96; P < 0.0001), and thrombocytopenia (131.85 ± 39.32 vs. 839.50 ± 171.20; P < 0.0001), and the presence of blasts in the peripheral blood of mice (approximately 50% blasts; P < 0.0001), 15 days after the transplants. These findings were corroborated through differential counts, flow cytometry, and in vivo imaging, which indicated increased number of immature cells in the bone marrow (15.75 ± 3.30 vs 6.69 ± 0.55; P < 0.001), peripheral blood (7.88 ± 2.67 vs 1.22 ± 0.89; P < 0.001), and spleen (35.21 ± 4.12 vs 1.35 ± 0.86; P < 0.0001), as well as promyelocytes in the bone marrow (41.23 ± 4.80 vs 5.73 ± 1.50; P < 0.0001), peripheral blood (46.08 ± 7.52 vs 1.10 ± 0.59; P < 0.0001) and spleen (35.31 ± 8.26 vs 2.49 ± 0.29; P < 0.0001) of PML/RARa mice. Compared to basal conditions of untransplanted mice, the PML/RARa mice exhibited frequencies of T lymphocytes CD4 helper = 14.85 ± 2.91 vs 20.77 ± 2.9 in the peripheral blood (P < 0.05); 12.75 ± 1.33 vs 45.90 ± 2.02 in the spleen (P < 0.0001); CD8 cytotoxic = 11.27 ± 3.44 vs 11.05 ± 1.22 in the peripheral blood (P > 0.05); 10.48 ± 1.16 vs 30.02 ± 1.80 in the spleen (P < 0.0001); natural killer (NK) cells = 3.68 ± 1.35 vs 6.84 ± 0.52 in the peripheral blood (P < 0.001); 4.43 ± 0.57 vs 6.40 ± 1.14 in the spleen (P < 0.05); B cells 2.50 ± 0.60 vs 15.20 ± 5.34 in the peripheral blood (P < 0.001); 17.77 ± 4.39 vs 46.90 ± 5.92 in the spleen (P < 0.0001); neutrophils = 5.97% ± 1.88 vs 31.57 ± 9.14 (P < 0.0001); and monocytes = 6.45 ± 2.97 vs 15.85 ± 2.57 (P < 0.001), selected as classical (3.33 ± 3.40 vs 57.80 ± 16.51, P < 0.0001), intermediate (57.42 ± 10.61 vs 21.75 ± 5.90, P < 0.0001), and non-classical monocytes (37.51 ± 10.85 vs 18.08 ± 7.13, P < 0.05) in the peripheral blood; and as classically activated (M1) within in the bone marrow (3.70 ± 0.94 vs 1.88 ± 0.39, P < 0.05) and spleen 15.19 ± 3.32 vs 9.47 ± 1.61, P < 0.05), in addition to alternatively activated (M2) macrophages within the bone marrow (23.06 ± 5.25 vs 1.76 ± 0.74, P < 0.0001) and spleen (46.51 ± 11.18 vs 30.58 ± 2.64, P < 0.05) compartments. All-trans retinoic acid (ATRA) treatment of PML/RARa mice reduced blast (immature cells) in the bone marrow (8.62 ± 1.81 vs 15.76 ± 1.25; P < 0.05) and spleen (8.75 ± 1.31 vs 35.21 ± 1.55; P < 0.0001) with no changes in the peripheral blood (10.13 ± 3.33 vs 7.88 ± 1.01; P > 0.05), as well as reduced promyelocytes in the bone marrow (19.79 ± 4.84 vs 41.23 ± 1.81; P < 0.05), peripheral blood (31.65 ± 3.92 vs 46.09 ± 2.84; P < 0.05) and spleen (24.84 ± 2.03 vs 41.46 ± 2.39; P < 0.001), and increased neutrophils of the peripheral blood (35.48 ± 7.24 vs 7.83 ± 1.40; P < 0.05) which was corroborated by reducing of immature cells and increase of neutrophil in the stained smears from PML/RARa mice, thus confirming that this model can be used in drug development studies. Our results show the effective induction of PML/RARa leukemia in BALB/c mice, thus producing a low-priced and reliable tool for investigating cellular immune responses in leukemia." @default.
• W4385973380 created "2023-08-19" @default.
• W4385973380 creator A5009984203 @default.
• W4385973380 creator A5011745884 @default.
• W4385973380 creator A5016618534 @default.
• W4385973380 creator A5041497834 @default.
• W4385973380 creator A5044078596 @default.
• W4385973380 creator A5052529953 @default.
• W4385973380 creator A5052609322 @default.
• W4385973380 creator A5088375418 @default.
• W4385973380 date "2023-12-01" @default.
• W4385973380 modified "2023-10-14" @default.
• W4385973380 title "PML/RARa leukemia induced murine model for immunotherapy evaluation" @default.
• W4385973380 cites W1579062391 @default.
• W4385973380 cites W1975350453 @default.
• W4385973380 cites W1976665833 @default.
• W4385973380 cites W1998238577 @default.
• W4385973380 cites W1999713403 @default.
• W4385973380 cites W2010972415 @default.
• W4385973380 cites W2011302069 @default.
• W4385973380 cites W2012661561 @default.
• W4385973380 cites W201291539 @default.
• W4385973380 cites W2018788643 @default.
• W4385973380 cites W2027530330 @default.
• W4385973380 cites W2033643758 @default.
• W4385973380 cites W2043496952 @default.
• W4385973380 cites W2045977586 @default.
• W4385973380 cites W2047008143 @default.
• W4385973380 cites W2054472394 @default.
• W4385973380 cites W2066067246 @default.
• W4385973380 cites W2078863277 @default.
• W4385973380 cites W2079526924 @default.
• W4385973380 cites W2084825289 @default.
• W4385973380 cites W2089573422 @default.
• W4385973380 cites W2099777707 @default.
• W4385973380 cites W2101150670 @default.
• W4385973380 cites W2124789340 @default.
• W4385973380 cites W2139310798 @default.
• W4385973380 cites W2161875667 @default.
• W4385973380 cites W2163204875 @default.
• W4385973380 cites W2308769951 @default.
• W4385973380 cites W2418008060 @default.
• W4385973380 cites W2474232167 @default.
• W4385973380 cites W2558231679 @default.
• W4385973380 cites W2599257356 @default.
• W4385973380 cites W2767388770 @default.
• W4385973380 cites W2909861102 @default.
• W4385973380 cites W2969169462 @default.
• W4385973380 cites W3159374759 @default.
• W4385973380 cites W4231346141 @default.
• W4385973380 doi "https://doi.org/10.1016/j.trim.2023.101919" @default.
• W4385973380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37598913" @default.
• W4385973380 hasPublicationYear "2023" @default.
• W4385973380 type Work @default.
• W4385973380 citedByCount "0" @default.
• W4385973380 crossrefType "journal-article" @default.
• W4385973380 hasAuthorship W4385973380A5009984203 @default.
• W4385973380 hasAuthorship W4385973380A5011745884 @default.
• W4385973380 hasAuthorship W4385973380A5016618534 @default.
• W4385973380 hasAuthorship W4385973380A5041497834 @default.
• W4385973380 hasAuthorship W4385973380A5044078596 @default.
• W4385973380 hasAuthorship W4385973380A5052529953 @default.
• W4385973380 hasAuthorship W4385973380A5052609322 @default.
• W4385973380 hasAuthorship W4385973380A5088375418 @default.
• W4385973380 hasConcept C104317684 @default.
• W4385973380 hasConcept C126322002 @default.
• W4385973380 hasConcept C203014093 @default.
• W4385973380 hasConcept C2776601000 @default.
• W4385973380 hasConcept C2778461978 @default.
• W4385973380 hasConcept C2778923028 @default.
• W4385973380 hasConcept C2780007613 @default.
• W4385973380 hasConcept C2780931953 @default.
• W4385973380 hasConcept C2781121885 @default.
• W4385973380 hasConcept C553184892 @default.
• W4385973380 hasConcept C55493867 @default.
• W4385973380 hasConcept C71924100 @default.
• W4385973380 hasConcept C86803240 @default.
• W4385973380 hasConcept C8891405 @default.
• W4385973380 hasConceptScore W4385973380C104317684 @default.
• W4385973380 hasConceptScore W4385973380C126322002 @default.
• W4385973380 hasConceptScore W4385973380C203014093 @default.
• W4385973380 hasConceptScore W4385973380C2776601000 @default.
• W4385973380 hasConceptScore W4385973380C2778461978 @default.
• W4385973380 hasConceptScore W4385973380C2778923028 @default.
• W4385973380 hasConceptScore W4385973380C2780007613 @default.
• W4385973380 hasConceptScore W4385973380C2780931953 @default.
• W4385973380 hasConceptScore W4385973380C2781121885 @default.
• W4385973380 hasConceptScore W4385973380C553184892 @default.
• W4385973380 hasConceptScore W4385973380C55493867 @default.
• W4385973380 hasConceptScore W4385973380C71924100 @default.
• W4385973380 hasConceptScore W4385973380C86803240 @default.
• W4385973380 hasConceptScore W4385973380C8891405 @default.
• W4385973380 hasFunder F4320320997 @default.
• W4385973380 hasFunder F4320321091 @default.
• W4385973380 hasFunder F4320321992 @default.
• W4385973380 hasFunder F4320322025 @default.
• W4385973380 hasLocation W43859733801 @default.
• W4385973380 hasLocation W43859733802 @default.

• next